Chapin Davis’s Heart Test Laboratories HSCS Stock Holding History

Chapin Davis’s Portfolio HSCS Stock Details HSCS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-150	Closed	-$1.75K	–	237
2024 Q1	$1.75K	Hold	150	–	–	﹤0.01%	232
2023 Q4	$2.56K	Sell	150 -400	-73%	-$9.85K	﹤0.01%	216
2023 Q3	$23.4K	Hold	550	–	–	0.01%	197
2023 Q2	$49.8K	Hold	550	–	–	0.02%	212
2023 Q1	$54.3K	Hold	550	–	–	0.03%	211
2022 Q4	$46.2K	Buy	+550	New	+$86.1K	0.03%	193

Other funds holding HSCS

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Cultivar Capital Denton, Texas $155M AUM 16.34% 1-Year Est. Return

OLVIG

Oliver Lagore Vanvalin Investment Group Flint, Michigan $255M AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Chapin Davis's HSCS Position: Q2 2024 in Review

Chapin Davis sold out of Heart Test Laboratories (HSCS) in Q2 2024, closing a stake of 150 shares — an estimated $1.75K sold.

Chapin Davis first reported a position in HSCS in Q4 2022 and held it in 6 quarters. The position peaked at $54.3K in Q1 2023. 7 funds tracked by Wall St. Rank hold HSCS as of Q2 2024.

Chapin Davis reported no remaining Heart Test Laboratories position as of Q2 2024 after selling out during the quarter.
Chapin Davis sold 150 Heart Test Laboratories shares in Q2 2024, an estimated $1.75K.
Chapin Davis first reported a position in Heart Test Laboratories in Q4 2022 and held it in 6 quarters.
Chapin Davis's Heart Test Laboratories position peaked at $54.3K in Q1 2023.
7 funds tracked by Wall St. Rank held Heart Test Laboratories as of Q2 2024.

Based on Chapin Davis's 13F filing for Q2 2024, filed 19 Jul 2024.